Sally Church, PhD has published an insightful post on Pharma Strategy Blog that provides an update on KRAS and NRAS mutations in colorectal cancer (CRC).
The blog post discusses in detail a recent paper by Douillard et al, published in the New England of Journal Medicine (NEJM) that shows a clear benefit of adding anti-EGFR monoclonal antibody panitumumab (Vectibix) to standard chemotherapy in patients without RAS mutations.
Dr Douillard concludes that better selection of patients in 1st line treatment of metastatic colorectal cancer based on mutational status will lead to better outcomes. Lung cancer specialists routinely use mutational analysis to make treatment decisions, so this conclusion is perhaps not surprising, and only shows that CRC treatment has lagged behind. It remains a disease where more effective treatment options are needed.
Do read Sally’s Pharma Strategy blog post (open access) if you’d like to learn more about how mutational analysis impacts anti-EGFR therapy in CRC.